We therefore tested whether combining the MEK inhibitor trametinib and the ERK1/2 nuclear translocation inhibitor EPE peptide, could overcome the drug resistance (or lack of response) that metastatic melanoma cells showed when treated with each drug individually. This evidence concerns the gene MAPK3 and melanoma.